COVID-19 Treatment and Drug Interactions in Oncology

Author/Presenter
Alisha Shivji
Category
Drug Interactions
Year Created
2022
Details

References

  1. Centers for Disease Control and Prevention. (2022, June 15). Underlying Medical Conditions Associated with High Risk for Severe COVID-19: Information for Healthcare Professionals. Retrieved from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html

  2. Centers for Disease Control and Prevention. (2022, September 26). Therapeutic Management of Nonhospitalized Adults with COVID-19. Retrieved from: https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/nonhospitalized-adults--therapeutic-management/

  3. Nirmatrelvir and ritonavir. Lexi-Drugs. Hudson, OH. Lexicomp, 2022. http://online.lexi.com/. Updated September 28, 2022. Accessed September 30, 2022.       

  4. Canada’s Drug and Health Technology Agency. (2022, January 28). Nirmatrelvir and Ritonavir (Paxlovid) for Mild to Moderate COVID-19. Retrieved from: https://www.cadth.ca/nirmatrelvir-and-ritonavir-paxlovid-mild-moderate-covid-19

  5. Liverpool Drug Interactions Group. (2022, May 19). Guidance for resuming paused or dose-adjusted comedications with Paxlovid. Retrieved from: https://www.covid19-druginteractions.org/prescribing_resources